
Quarterly Reports

for the period ended September 30, 2026



CONTENTS

COMPANY INFORMATION	02
DIRECTORS' REPORT (ENGLISH VERSION).....	03
DIRECTORS' REPORT (URDU VERSION).....	06
CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION	09
CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS	10
CONDENSED INTERIM STATEMENT OF COMPREHENSIVE INCOME	11
CONDENSED INTERIM STATEMENT OF CASH FLOWS.....	12
CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY	13
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS	14

COMPANY INFORMATION

BOARD OF DIRECTORS	: Mr. Mikio Bando (Chairman) (Alternate: Mr. Hideshi Tsunezawa) Mr. Moin ur Rehman (Director and Chief Executive Officer) Mr. Jun Chihara Mr. Tariq Mehtab Feroz Mr. Suhari Mukti (Alternate: Mr. Tauseef Ahmed Shaikh) Mr. Abid Hussain (Independent Director) Mrs. Navin Salim Merchant (Independent Director)
CHIEF FINANCIAL OFFICER	: Mr. Tauseef Ahmed Shaikh
COMPANY SECRETARY	: Mr. Amir Khalid
AUDIT COMMITTEE	: Mr. Abid Hussain (Chairman) Mr. Jun Chihara (Member) Mr. Tariq Mehtab Feroz (Member)
HEAD OF INTERNAL AUDIT	: Mr. Jawaid Noor (Secretary)
RISK MANAGEMENT & SUSTAINABILITY COMMITTEE	: Mr. Abid Hussain (Chairman) Mr. Jun Chihara (Member) Mr. Moin ur Rehman (Member) Mrs. Navin Salim Merchant (Female Member of Sustainability Committee Only) Mr. Tauseef Ahmed Shaikh (Secretary)
HUMAN RESOURCE REMUNERATION & NOMINATION COMMITTEE	: Mrs. Navin Salim Merchant (Chairperson) Mr. Jun Chihara (Member) Mr. Tariq Mehtab Feroz (Member) Mr. Moin ur Rehman (Member) Mr. David Sunil (Secretary)
AUDITORS (EXTERNAL)	: Yousuf Adil Chartered Accountants
AUDITORS (INTERNAL)	: M. M. Hussain & Co, (Chartered Accountants)
LEGAL ADVISOR	: Dr. Moneeba Hamid
BANKERS	: Citibank N.A., Habib Metropolitan Bank Limited Meezan Bank Limited (Shariah), Habib Bank Limited, Bank Al-Habib Limited Bank Alfalah Islamic (Shariah), Bank Alfalah Limited Allied Bank Limited MCB Bank Limited, National Bank of Pakistan
REGISTERED OFFICE	: Head Office: 30-B, Sindhi Muslim Co-operative, Housing Society, Karachi-74400 Tel.: 34528651 – 4, E-mail: secretarialcompliance@otsuka.pk Web site: www.otsuka.pk Factory: Plot No. F/4-9, Hub Industrial Trading Estate, Distt. Lasbella (Balochistan) Tel.: (0853) 303517-8, Fax: (0853) 303519
SHARE REGISTRAR	: M/s. THK Associates (Pvt.) Limited, Plot No. 32-C, Jami Commercial Street # 2, D.H.A., Phase VII, Karachi. Customer Support Services Tel No. (0092-21) 111-000-322 Fax: (0092-21) 35310191 Email: sfc@thk.com.pk.

DIRECTORS' REPORT

The Directors of Otsuka Pakistan Limited (the “Company”) are pleased to present the financial statements for the first quarter ended September 30, 2026.

Board of Directors

The Board of Directors as required under section 159 of the Companies Act, 2017 had fixed the number of Directors have been elected at seven (7) including two (2) independent directors who will represent the minority shareholders of the Company in accordance with the provisions of the Listed Companies (Code of Corporate Governance) Regulations 2019, for a period of three years commenced from November 01, 2024.

The composition of Board of Directors (“the Board”) is as follows:

CATEGORY	NAMES	GENDER
Executive Director	Mr. Moin ur Rehman (CEO)	Male
Non-Executive Directors	Mr. Mikio Bando (Chairman) *	
	Mr. Tariq Mehtab Feroz	
	Mr. Jun Chihara **	
	Mr. Suhari Mukti***	
Independent Directors	Mr. Abid Hussain	Female
	Mrs. Navin Salim Merchant	

* Mr. Hideshi Tsunazawa is the alternate director of Mr. Mikio Bando.

** Mr. Jun Chihara has been appointed as director in place of Mr. Kimitaka Naito w.e.f. April 22, 2026.

*** Mr. Tauseef Ahmed Shaikh is the alternate director of Mr. Suhari Mukti.

Board Sub-Committees

NAME OF BOARD SUB-COMMITTEE	NAME OF MEMBER
Audit Committee	Mr. Abid Hussain (Chairman) Mr. Jun Chihara Mr. Tariq Mehtab Feroz Mr. Jawaid Noor (Secretary)
Human Resource Remuneration & Nomination Committee	Mrs. Navin Salim Merchant (Chairperson) Mr. Moin ur Rehman Mr. Jun Chihara Mr. Tariq Mehtab Feroz Mr. David Sunil (Secretary)
Risk Management and Sustainability Committee	Mr. Abid Hussain (Chairman) Mr. Moin ur Rehman Mr. Jun Chihara Mrs. Navin Salim Merchant Mr. Tauseef Ahmed Shaikh (Secretary)

Directors' Remuneration

The Board has a formal policy and transparent procedures for the remuneration of its directors in accordance with the Companies Act, 2017 and the Listed Companies (Code of Corporate Governance) Regulations 2017. Currently, the two independent directors and a non-executive director are getting fixed fees for attending the board meetings. The aggregate amount of remuneration paid to each director of the Company during the year is given below:

CATEGORY	NAMES	NATURE OF REMUNERATION	AMOUNT (Rs. In '000)
Executive Director	Mr. Moin ur Rehman (CEO)	Salaries and benefits	7,521
Non-Executive Directors	Mr. Mikio Bando (Chairman)	Not applicable	Nil
	Mr. Tariq Mehtab Feroz	Meeting Fees	75
	Mr. Jun Chihara	Not Applicable	Nil
	Mr. Suhari Mukti	Not applicable	Nil
Independent Directors	Mr. Abid Hussain	Meeting Fees	75
	Mrs. Navin Salim Merchant	Meeting Fees	75

Business Review

During the first quarter of FY2026-27, Otsuka Pakistan Limited delivered a positive financial performance, achieving revenue of Rs. 1,147 million, representing growth of 6.6% over Rs. 1,076 million recorded in the corresponding quarter of the previous year. This growth was primarily supported by continued momentum in Clinical Nutrition business and improved market penetration. The Company's gross profit increased significantly to Rs. 489 million, i.e. 42.7%, compared with Rs. 339 million in the corresponding period last year mainly driven by PN & EN products and improved margins in BIV business owing to sustained production and reduced rejection due to series of improvements and CAPEX investments at OPL factory in last 2 years.

Operating profit rose to Rs. 235 million, i.e. 20.4% from Rs. 180 million, while profit after taxation increased to Rs. 138 million, i.e. 12% from Rs. 120 million. Selling and distribution expenses increased by 13.3%, primarily driven by higher promotional expenditures of newly launched products and higher freight costs. Other expenses have significantly increased by 175% particularly due to depreciation of local currency which resulted in net exchange loss of Rs. 28. million for the period ended September 30, 2026 on foreign currency loan of group company.

Overall, the first quarter performance demonstrated improved gross margins, effective control over the cost of sales, and continued growth in the company's profitable segments. The Company remains focused on strengthening operational efficiency, maintaining product quality, expanding its clinical nutrition portfolio, and delivering sustainable financial performance.

Future Outlook

The Board remains cautiously optimistic about FY2026–27, while recognizing the challenges posed by economic uncertainty, inflationary pressures, exchange rate volatility, and evolving geopolitical developments resulting in procurement delays and challenges in maintaining the availability of raw

material. Additionally, closure of Pakistan–Afghanistan border for trade and limited ban on crossing of Afghanistan patient continues to affect export sales.

Company's strategic priorities include strengthening manufacturing capabilities through massive planned capital expenditures, improving operational systems, enhancing supply-chain efficiency and deepening market penetration, which will support sustainable growth and further strengthen the Company's position across its key business segments. Additionally, the Company plans to introduce another product in the Enteral Nutrition (EN) category, Once Renal, to be imported from Thailand, by the end of the current year.

Effective from 1 January 2027, Manufacturing of the Company's 1,000 ml products is planned to be shifted from Production Line-II to Production Line-I to optimize capacity utilization and operational efficiency.

Otsuka Pakistan Limited remains committed to managing emerging risks, maintaining business continuity, strengthening profitability, and creating sustainable long-term value for its shareholders and all other stakeholders.

Acknowledgment

The Board sincerely appreciates the dedication and commitment of our employees and the continued trust of our shareholders, business partners, and customers. Their support motivates us to pursue excellence and maintain our commitment to growth and innovation.

On behalf of the Board



Moin ur Rehman
Chief Executive Officer



Abid Hussain
Director

Dated: October 28, 2026

ڈائریکٹرز کی رپورٹ

اوسٹوکا پاکستان لمیٹڈ ("کمپنی") کے ڈائریکٹرز 30 ستمبر 2026 کو ختم ہونے والی پہلی سہ ماہی کے مالی گوشوارے پیش کرتے ہوئے مسرت محسوس کرتے ہیں۔

بورڈ آف ڈائریکٹرز

کمپنیز ایکٹ، 2017 کی دفعہ 159 کے تقاضوں کے مطابق بورڈ آف ڈائریکٹرز کی تعداد سات (7) مقرر کی گئی ہے، جن میں دو (2) آزاد ڈائریکٹرز شامل ہیں۔ یہ آزاد ڈائریکٹرز لسٹڈ کمپنیز (کارپوریٹ گورننس کوڈ) ریگولیشنز 2019 کے مطابق کمپنی کے اقلیتی حصص یافتگان کی نمائندگی کرتے ہیں۔ ان کی تین سالہ مدت یکم نومبر 2024 سے شروع ہوئی۔

بورڈ آف ڈائریکٹرز ("بورڈ") کی تشکیل درج ذیل ہے:

جنس	نام	زمرہ
مرد	جناب معین الرحمٰن (چیف ایگزیکٹو آفیسر)	ایگزیکٹو ڈائریکٹر
مرد	جناب میکو بانڈو (چیئرمین) *	نان ایگزیکٹو ڈائریکٹر
مرد	جناب طارق مہتاب فیروز	نان ایگزیکٹو ڈائریکٹر
مرد	جناب جون چہارا **	نان ایگزیکٹو ڈائریکٹر
مرد	جناب سہاری مکتی ***	نان ایگزیکٹو ڈائریکٹر
مرد	جناب عابد حسین	آزاد ڈائریکٹر
خاتون	محترمہ نوین سلیم مرچنٹ	آزاد ڈائریکٹر

* ہیدیشی سونیزاوا، میکو بانڈو کے متبادل ڈائریکٹر ہیں۔

** جون چہارا کو کیمیتا کا نائیتو کی جگہ 22 اپریل 2026 سے ڈائریکٹر مقرر کیا گیا۔

*** توصیف احمد شیخ، سہاری مکتی کے متبادل ڈائریکٹر ہیں۔

بورڈ کی ذیلی کمیٹیاں

کمیٹی کا نام	اراکین کے نام
آڈٹ کمیٹی	جناب عابد حسین (چیئرمین) جناب جون چہارا جناب طارق مہتاب فیروز جناب جاوید نور (سیکرٹری)
بیومن ریسورس، معاوضہ اور نامزدگی کمیٹی	محترمہ نوین سلیم مرچنٹ (چیئرپرسن) جناب معین الرحمٰن جناب جون چہارا جناب طارق مہتاب فیروز جناب ڈیوڈ سنیل (سیکرٹری)
رسک مینجمنٹ اور پائیداری کمیٹی	جناب عابد حسین (چیئرمین) جناب معین الرحمٰن جناب جون چہارا محترمہ نوین سلیم مرچنٹ جناب توصیف احمد شیخ (سیکرٹری)

ڈائریکٹرز کے معاوضے

کمپنیز ایکٹ، 2017 اور لسٹڈ کمپنیز (کارپوریٹ گورننس کوڈ) ریگولیشنز 2017 کے مطابق بورڈ نے ڈائریکٹرز کے معاوضے کے لیے باقاعدہ پالیسی اور شفاف طریقہ کار وضع کیا ہے۔ فی الحال دونوں آزاد ڈائریکٹرز اور ایک نان ایگزیکٹو ڈائریکٹر بورڈ اجلاسوں میں شرکت کے عوض مقررہ فیس وصول کرتے ہیں۔ سال کے دوران کمپنی کے ہر ڈائریکٹر کو ادا کیے گئے معاوضے کی مجموعی تفصیل ذیل میں دی گئی ہے:

زمرہ	نام	معاوضے کی نوعیت	رقم (ہزار روپے میں)
ایگزیکٹو ڈائریکٹر	جناب معین الرحمن (چیف ایگزیکٹو آفیسر)	تنخواہ اور مراعات	7,521
نان ایگزیکٹو ڈائریکٹر	جناب میکو بانڈو (چیئرمین)	لاگو نہیں	صفر
نان ایگزیکٹو ڈائریکٹر	جناب طارق مہتاب فیروز	اجلاس میں شرکت کی فیس	75
نان ایگزیکٹو ڈائریکٹر	جناب جون چیہارا	لاگو نہیں	صفر
نان ایگزیکٹو ڈائریکٹر	جناب سوہاری مکتی	لاگو نہیں	صفر
آزاد ڈائریکٹر	جناب عابد حسین	اجلاس میں شرکت کی فیس	75
آزاد ڈائریکٹر	محترمہ نوین سلیم مرچنٹ	اجلاس میں شرکت کی فیس	75

کاروباری کارکردگی کا جائزہ

مالی سال 2026-27 کی پہلی سہ ماہی کے دوران اوٹسوکا پاکستان لمیٹڈ نے مثبت مالی کارکردگی کا مظاہرہ کرتے ہوئے 1,147 ملین روپے کی آمدنی حاصل کی، جو گزشتہ سال کی اسی سہ ماہی میں ریکارڈ کی گئی 1,076 ملین روپے کی آمدنی کے مقابلے میں 6.6 فیصد اضافہ ظاہر کرتی ہے۔ اس نمو میں کلینیکل نیوٹریشن کے کاروبار میں مسلسل پیش رفت اور مارکیٹ میں رسائی میں بہتری نے اہم کردار ادا کیا۔ کمپنی کا مجموعی منافع گزشتہ سال کی اسی مدت کے 339 ملین روپے کے مقابلے میں نمایاں طور پر بڑھ کر 489 ملین روپے ہو گیا، جو آمدنی کا 42.7 فیصد بنتا ہے۔ اس بہتری کی بنیادی وجوہات میں پی این (PN) اور ای این (EN) مصنوعات کی بہتر کارکردگی اور بی آئی وی (BIV) کاروبار میں منافع کی شرح میں اضافہ شامل ہیں، جو مسلسل پیداوار، مصنوعات کے مسترد ہونے کی شرح میں کمی اور گزشتہ دو سال کے دوران او پی ایل فیکٹری میں کی جانے والی مختلف بہتریوں اور سرمایہ جاتی اخراجات (CAPEX) کی سرمایہ کاری کے نتیجے میں ممکن ہوا۔

آپریٹنگ منافع 180 ملین روپے سے بڑھ کر 235 ملین روپے ہو گیا، جو سیلز کا 20.4 فیصد ہے، جبکہ بعد از ٹیکس منافع 120 ملین روپے سے بڑھ کر 138 ملین روپے ہو گیا، جو سیلز کا 12 فیصد ہے۔ فروخت اور تقسیم کے اخراجات میں 13.3 فیصد اضافہ ہوا، جس کی بنیادی وجوہات میں نئی متعارف کرائی گئی مصنوعات کی تشہیری سرگرمیوں پر زیادہ اخراجات اور مال برداری کے اخراجات میں اضافہ شامل ہیں۔ دیگر اخراجات میں بھی نمایاں طور پر 175 فیصد اضافہ ہوا، جس کی بنیادی وجہ مقامی کرنسی کی قدر میں کمی ہے۔ اس کے نتیجے میں 30 ستمبر 2026 کو ختم ہونے والی مدت کے دوران گروپ کمپنی کے غیر ملکی کرنسی کے قرض پر 28 ملین روپے کا خالص زر مبادلہ نقصان ہوا۔

مجموعی طور پر، پہلی سہ ماہی کی کارکردگی میں مجموعی منافع کی شرح میں بہتری، فروخت کی لاگت پر مؤثر کنٹرول اور کمپنی کے منافع بخش شعبوں میں مسلسل ترقی دیکھنے میں آئی۔ کمپنی آپریشنل کارکردگی کو مزید بہتر بنانے، مصنوعات کے معیار کو برقرار رکھنے، کلینیکل نیوٹریشن کی مصنوعات کے پورٹ فولیو کو وسعت دینے اور پائیدار مالی کارکردگی کے حصول پر توجہ مرکوز کیے ہوئے ہے۔

مستقبل کا منظرنامہ

بورڈ مالی سال 2026-27 کے بارے میں محتاط طور پر پرامید ہے، تاہم معاشی غیر یقینی صورتِ حال، افراطِ زر کے دباؤ، شرح مبادلہ میں اتار چڑھاؤ اور بدلتی ہوئی جغرافیائی سیاسی صورتِ حال سے پیدا ہونے والے چیلنجز کو تسلیم کرتا ہے۔ ان عوامل کے باعث خریداری میں تاخیر اور خام مال کی دستیابی برقرار رکھنے میں مشکلات پیش آ رہی ہیں۔ مزید یہ کہ پاکستان اور افغانستان کی سرحد تجارت کے لیے بند ہونے اور افغان مریضوں کی آمدورفت پر محدود پابندی کے باعث برآمدی فروخت مسلسل متاثر ہو رہی ہے۔

کمپنی کی حکمتِ عملی کی ترجیحات میں بڑے پیمانے پر منصوبہ بند سرمایہ جاتی اخراجات کے ذریعے پیداواری صلاحیت کو مضبوط بنانا، آپریشنل نظام بہتر کرنا، سپلائی چین کی کارکردگی میں اضافہ اور مارکیٹ میں رسائی کو مزید وسیع کرنا شامل ہے۔ یہ اقدامات پائیدار ترقی میں معاون ہوں گے اور کمپنی کے اہم کاروباری شعبوں میں اس کی پوزیشن کو مزید مستحکم کریں گے۔ مزید برآں، کمپنی کا منصوبہ ہے کہ رواں سال کے اختتام تک انٹرل نیوٹریشن (EN) کے شعبے میں ایک اور مصنوعات، اونس رینل، تھائی لینڈ سے درآمد کر کے متعارف کرائی جائے۔

پیداواری گنجائش کے بہتر استعمال اور آپریشنل کارکردگی میں اضافے کے لیے کمپنی کی 1,000 ملی لیٹر مصنوعات کی تیاری یکم جنوری 2027 سے پروڈکشن لائن-II سے پروڈکشن لائن-I میں منتقل کرنے کا منصوبہ ہے۔

اوٹسوکا پاکستان لمیٹڈ نئے ابھرتے ہوئے خطرات کے انتظام، کاروباری تسلسل برقرار رکھنے، منافع میں اضافہ کرنے اور حصص یافتگان سمیت تمام متعلقہ فریقوں کے لیے طویل مدتی پائیدار قدر پیدا کرنے کے عزم پر قائم ہے۔


اظہارِ تشکر

بورڈ اپنے ملازمین کی لگن اور وابستگی، نیز حصص یافتگان، کاروباری شراکت داروں اور صارفین کے مسلسل اعتماد کو خلوصِ دل سے سراہتا ہے۔ ان کی معاونت ہمیں بہترین کارکردگی، ترقی اور جدت کے لیے اپنے عزم کو برقرار رکھنے کی ترغیب دیتی ہے۔

بورڈ کی جانب سے

کراچی

بتاریخ: 28 اکتوبر 2026



عابد حسین

ڈائریکٹر



معین الرحمان

چیف ایگزیکٹو آفیسر


CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION AS AT SEPTEMBER 30, 2026

AS AT SEPTEMBER 30, 2026		(Unaudited) September 30, 2026	(Audited) June 30, 2026
	Note	-----Rupees in '000-----	
ASSETS			
Non-current assets			
Property, plant and equipment	4	668,503	661,792
Intangible assets		983	1,150
Long-term loans		7,284	6,366
Long-term deposits		1,497	1,497
Deferred tax asset - net		34,631	60,698
		712,898	731,503
Current assets			
Stores and spares		77,772	82,307
Stock-in-trade		1,331,264	1,300,451
Trade debts		168,336	183,452
Loans and advances		67,903	28,976
Trade deposits, short-term prepayments and other receivables		32,203	32,316
Sales tax refundable		47,172	47,172
Advance tax - net		11,670	64,344
Short-term investment		564,610	464,610
Bank balances		67,932	87,144
		2,368,862	2,290,772
Total assets		3,081,760	3,022,275
EQUITY AND LIABILITIES			
Equity			
Share capital	5	121,000	121,000
Revenue reserves		1,177,586	1,039,969
Total equity		1,298,586	1,160,969
Liabilities			
Non-current liabilities			
Lease liability		5,895	-
Current liabilities			
Short-term loan from a related party	6	971,135	942,700
Trade and other payables		799,483	890,958
Current portion of lease liability		1,351	22,513
Unclaimed dividend		1,908	1,908
Mark-up accrued		3,402	3,227
		1,777,279	1,861,306
Total equity and liabilities		3,081,760	3,022,275
Contingencies and commitments			
	7		

The annexed notes 1 to 13 form an integral part of this condensed interim financial information.



Moin ur Rehman
Chief Executive Officer



Abid Hussain
Director



Tauseef Ahmed Shaikh
Chief Financial Officer

**CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UNAUDITED)
FOR THE QUARTER ENDED SEPTEMBER 30, 2026**

	Note	Quarter ended September 30,	
		2026	2025
		----- Rupees in '000 -----	
Revenue from contract with customers	8	1,147,351	1,076,104
Cost of sales		(657,866)	(736,731)
Gross profit		489,485	339,373
Selling and distribution expenses		(179,104)	(158,141)
Administrative and general expenses		(53,890)	(45,743)
		256,491	135,489
Other income		32,042	64,034
		288,533	199,523
Other expenses		(53,998)	(19,658)
Operating profit		234,535	179,864
Finance cost		(4,812)	(2,533)
Profit before levies and taxation		229,723	177,331
Levies		-	(119)
Profit before taxation		229,723	177,212
Taxation		(92,106)	(57,134)
Profit for the period		137,617	120,078
		----- Rupees -----	
Earning per share - basic and diluted		11.37	9.92

The annexed notes 1 to 13 form an integral part of this condensed interim financial information.



Moin ur Rehman
Chief Executive Officer



Abid Hussain
Director



Tauseef Ahmed Shaikh
Chief Financial Officer


**CONDENSED INTERIM STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED)
FOR THE QUARTER ENDED SEPTEMBER 30, 2026**

	Quarter ended September 30,	
	2026	2025
	----- Rupees in '000 -----	
Profit for the period	137,617	120,078
Other comprehensive income	-	-
Total comprehensive income for the period	<u>137,617</u>	<u>120,078</u>

The annexed notes 1 to 13 form an integral part of this condensed interim financial information.



Moin ur Rehman
Chief Executive Officer



Abid Hussain
Director



Tauseef Ahmed Shaikh
Chief Financial Officer

**CONDENSED INTERIM STATEMENT OF CASH FLOWS (UNAUDITED)
FOR THE QUARTER ENDED SEPTEMBER 30, 2026**


Note	Quarter ended September 30,	
	2026	2025
	----- Rupees in '000 -----	
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before levies and taxation	229,723	177,331
Adjustment for non-cash charges and other items:		
Depreciation & amortisation	34,802	30,283
Unrealized exchange (gain) / loss - net	28,435	(38,500)
Finance cost	4,812	2,533
Operating Cashflows before working capital changes	297,772	171,647
(Increase) / decrease in current assets		
Stores and spares	4,535	(6,422)
Stock-in-trade	(30,813)	(16,434)
Trade debts	15,116	(2,423)
Loans and advances	(38,927)	10,965
Trade deposits, short-term prepayments and other receivables	113	(4,460)
	(49,976)	(18,774)
Increase / (decrease) in current liabilities		
Trade and other payables	(81,945)	10,149
Cash generated from operations	165,851	163,022
Finance cost paid	(4,637)	(2,490)
Taxes paid	(13,365)	(35,531)
(Increase) / decrease in long-term loans	(918)	156
Net cash generated from operations	146,931	125,157
CASH FLOWS FROM INVESTING ACTIVITIES		
Additions to property, plant and equipment	(41,346)	(46,613)
Net cash used in investing activities	(41,346)	(46,613)
CASH FLOWS FROM FINANCING ACTIVITIES		
Lease rentals paid	(24,797)	-
Net cash used in financing activities	(24,797)	-
Net increase in cash and cash equivalents	80,788	78,544
Cash and cash equivalents at the beginning of the period	551,754	378,817
Cash and cash equivalents at the end of the period	632,542	457,361

10

The annexed notes 1 to 13 form an integral part of this condensed interim financial information.



Moin ur Rehman
Chief Executive Officer



Abid Hussain
Director



Tauseef Ahmed Shaikh
Chief Financial Officer


**CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY (UNAUDITED)
FOR THE QUARTER ENDED SEPTEMBER 30, 2026**

	Issued, subscribed and paid-up capital	Revenue reserves			Total
		General reserve	Unappropriated profits	Sub-total	
	----- Rupees in '000 -----				
Balance as at June 30, 2025 (audited)	121,000	491,980	82,799	574,779	695,779
Total comprehensive loss for the period ended Sep 30, 2025	-	-	120,078	120,078	120,078
	-	-			
Balance as at Sep 30, 2025	<u>121,000</u>	<u>491,980</u>	<u>202,877</u>	<u>694,857</u>	<u>815,857</u>
Balance as at June 30, 2026 (audited)	121,000	491,980	547,989	1,039,969	1,160,969
Total comprehensive income for the period ended Sep 30, 2026	-	-	137,617	137,617	137,617
Balance as at Sep 30, 2026	<u>121,000</u>	<u>491,980</u>	<u>685,606</u>	<u>1,177,586</u>	<u>1,298,586</u>

The annexed notes 1 to 13 form an integral part of this condensed interim financial information.



Moin ur Rehman
Chief Executive Officer



Abid Hussain
Director



Tauseef Ahmed Shaikh
Chief Financial Officer

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS (UN-AUDITED) FOR THE QUARTER ENDED SEPTEMBER 30, 2026

1. THE COMPANY AND ITS OPERATIONS

- 1.1 Otsuka Pakistan Limited (the Company) was incorporated in Pakistan in the month of February 1988 as a public limited company under the repealed Companies Ordinance, 1984 (now Companies Act, 2017) and is listed on the Pakistan Stock Exchange Limited. The Company is engaged in the manufacturing, marketing and distribution of intravenous infusions and trading in pharmaceutical products, nutritional foods and medical equipment. The Company is an indirect subsidiary of Otsuka Pharmaceutical Company Limited, Japan.

The geographical location and address of the Company's business units, including mill / plants, is as under:

Registered Office in Karachi	Purpose	Hub	Purpose
30-B, S.M.C.H. Society, Karachi	Head office	F/4-9, H.I.T.E., Hub, Balochistan, Hub Industrial And Trading Estates, Hub, Las Bela, Balochistan	Factory

2 BASIS OF PREPARATION

2.1 Statement of compliance

These condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. The accounting and reporting standards as applicable in Pakistan for interim financial reporting comprise of :

- International Accounting Standard 34: 'Interim Financial Reporting' (IAS - 34) issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017; and
- Provisions of and directives issued under the Companies Act, 2017.

Where the provisions of and directives issued under the Companies Act, 2017 differ from the requirements of IAS-34, the provisions of and directives issued under the Companies Act, 2017 have been followed.

The disclosures made in these condensed interim financial statements have, however, been limited based on the requirements of IAS-34. These condensed interim financial statements do not include all the information and disclosures which are required in a full set of financial statements and should be read in conjunction with the annual audited financial statements of the Company for the year ended June 30, 2026. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the financial position and performance since the latest annual financial statements of the Company. These condensed interim financial statements are unaudited.

The comparatives in the condensed interim statement of financial position as at September 30, 2026 have been extracted from the audited financial statements of the Company for the year ended June 30, 2026, whereas, the comparatives in the condensed interim statement of profit or loss, condensed interim statement of comprehensive income, condensed interim statement of changes in equity and condensed interim statement of cash flows have been extracted from the unaudited condensed interim financial statements of the Company for the quarter year ended September 30, 2025.

2.2 Basis of measurement

These condensed interim financial statements have been prepared under the historical cost convention except that obligations in respect of certain staff retirement benefits are carried at present value of defined benefit obligation less fair value of plan assets.

2.3 Functional and presentation currency

These condensed interim financial statements have been presented in Pak Rupees which is the functional and presentation currency of the Company.

3. MATERIAL ACCOUNTING AND RISK MANAGEMENT POLICIES, ESTIMATES AND JUDGMENTS

3.1 Material accounting policy information

3.1.1 The material accounting policy information and the methods of computation adopted in the preparation of these condensed interim financial statements are the same as those applied in the preparation of the annual audited financial statements for the year ended June 30, 2026.

3.1.2 Adoption of certain standards, interpretations and amendments

There are certain standards, interpretations on accounting and reporting standards as applicable in Pakistan and amendments to certain existing standards which have been published and are mandatory for the accounting period beginning on or after July 01, 2026. These standards, interpretations and amendments are either not relevant to the Company's operations or are not expected to have a significant impact on the accounting policies of the Company and therefore not disclosed in these condensed interim financial statements.

3.2 Financial risk management

The Company's financial risk management objective and policies are consistent with those disclosed in the annual audited financial statements of the Company for the year ended June 30, 2026.

3.3 Fair value of financial asset and liabilities

The carrying value of financial assets and financial liabilities reported in these condensed interim financial statements approximates their fair values.

3.4 Estimates and Judgements

Estimates and judgments made by management in the preparation of these condensed interim financial statements are same as those applied in the preparation of the annual audited financial statements of the Company for the year ended June 30, 2026.

	Note	(Un-audited) Sep 30, 2026	(Audited) June 30, 2026
		-----Rupees in '000-----	
4 PROPERTY, PLANT AND EQUIPMENT			
Operating fixed assets		610,019	622,432
Capital work-in-progress	4.2	58,484	39,360
		668,503	661,792

4.1 The following additions to and disposals of operating fixed assets have been made during the period:

	(Un-audited) Quarter ended Sep. 30, 2026		(Un-audited) Quarter ended Sep.30, 2025	
	Addition / transfer - at cost	Disposal - at net book value	Addition / transfer - at cost	Disposal - at net book value
	----- (Rupees '000) -----		----- (Rupees '000) -----	
Operating fixed assets				
Building on leasehold land	587	-	489	-
Plant and machinery	7,276	-	11,343	-
Furniture, fixtures and equipment	5,010	-	5,799	-
Vehicles	9,349	-	25,697	-
Total	22,222	-	43,328	-

16

9. TRANSACTIONS WITH RELATED PARTIES

Related parties include Otsuka Pharmaceutical Company Limited the holding company, associated companies / undertakings (namely Otsuka Pharmaceutical Factory Incorporation, Japan, Thai Otsuka Pharmaceutical Company Limited, Thailand, P.T. Otsuka Indonesia, Otsuka Pharmaceutical Company, Shanghai Micro port Medical (Group) Company Limited, etc.), Danish Enterprises, Qubittech, staff retirement funds and the key management personnel. Details of the transactions with the related parties and the balances with them as at period end other than those which have been disclosed else where are as follows:

9.1 Name and nature of relationship

Name of related party	Relationship with the Company	Nature of transaction	(Un-audited) Sep 30, 2026 ----Rupees in '000----	(Un-audited) Sep 30, 2025
Otsuka Pharmaceutical Factory Inc.	Associated undertaking	Mark up on loan	3,460	2,366
Otsuka Pharmaceutical Co, Ltd.	Parent Company	Purchases	33,745	20,371
Guangdong Otsuka Pharmaceutical Co., Ltd	Associated undertaking	Purchases	24,920	-
Thai Otsuka Pharmaceutical Co. Ltd.	Associated undertaking	Purchases	29,108	96,566
Director	Independent Director and Non Executive Director	Meeting fees	225	225
Otsuka staff provident fund	Provident fund	Contribution during the period to the fund	5,448	4,926
Key Management Personnel	Key Management Personnel	Remuneration paid	17,836	17,244

9.2 Purchases from related parties primarily represent purchase of raw materials and finished goods from Otsuka group companies.

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company. The Company considers all members of their management team, including the Chief Executive Officer and working directors to be its key management personnel.

Name of related party	Relationship with the Company	Nature of transaction	(Un-audited) Sep 30, 2026 ----Rupees in '000----	(Audited) Jun 30, 2026
Otsuka Pharmaceutical Factory Inc.	Associated undertaking	Short term loan payable Markup payable	971,135 3,460	942,700 3,227
Otsuka Pharmaceutical Co, Ltd.	Parent company	Payable against purchases	6,484	13,365
Guangdong Otsuka Pharmaceutical Co., Ltd	Associated undertaking	Payable against purchases	25,041	-
Thai Otsuka Pharmaceutical Co. Ltd.	Associated undertaking	Payable against purchases	29,051	20,255
Shareholders	Shareholders	Payable to shareholders	363	363
Otsuka staff provident fund	Provident fund	Payable to Employees Provident Fund	5,272	4,972
Otsuka staff gratuity fund	Gratuity fund	Payable to Staff Retirement Benefit Fund	17,868	12,007
Key Management Personnel	Key Management Personnel	Advance from key management personnel	-	330

10 CASH AND CASH EQUIVALENTS

Cash and cash equivalents included in the condensed interim cash flow statement comprise the following items included in the condensed interim balance sheet:

	(Un-audited) Sep 30, 2026	(Un-audited) Sep 30, 2025
	----Rupees in '000----	
- Bank balances	67,932	242,751
- Short term investments	564,610	214,610
	<u>632,542</u>	<u>457,361</u>

11 SEGMENT INFORMATION

11.1 This condensed interim financial information has been prepared on the basis of a single reportable segment.

11.2 Sales from Intravenous Solutions represent 90.1 percent while sales from others represent 9.9 percent (Sep.30, 2025: 89.81 percent and 10.19 percent) respectively of the total sales of the Company.

	(Un-audited) Sep 30, 2026	(Un-audited) Sep 30, 2025
	----- In percent -----	
11.3 The geographic segmentation of sales is as follows:		
Pakistan	100.00	93.26
Outside Pakistan (Exports)	-	6.74

11.4 All non-current assets of the Company as at September 30, 2026 are located in Pakistan.

12 DATE OF AUTHORISATION FOR ISSUE

These condensed interim financial statements were authorised for issue on October 28, 2026 by the Board of Directors of the Company.


13 GENERAL

13.1 Figures have been rounded off to the nearest thousand Rupees unless otherwise stated.

13.2 Corresponding figures have been rearranged and reclassified, wherever necessary, for the purpose of comparison, the effects of which are not material.



Moin ur Rehman
Chief Executive Officer



Abid Hussain
Director



Tauseef Ahmed Shaikh
Chief Financial Officer

www.otsuka.pk



A Sign of Japanese Commitment to Better Health